The graph at the 21-minute mark combines four studies that totaled over 1,200 patients...so I think that is a very substantial comparison.
In regard to the MMSE Cog-11 vs. Cog-13, do you know if the FDA approved Leqembi and Kisunla using Cog-13 or Cog-11?
In regard to the MMSE Cog-11 vs. Cog-13, do you know if the FDA approved Leqembi and Kisunla using Cog-13 or Cog-11?
Recent ANVS News
- Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 09:02:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:55:10 PM
- Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio • GlobeNewswire Inc. • 04/28/2026 12:00:00 PM
- Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission • GlobeNewswire Inc. • 04/10/2026 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/09/2026 09:09:42 PM
- Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants • GlobeNewswire Inc. • 04/09/2026 12:30:00 PM
- The Credibility Filter Wall Street Uses to Sort Biotech Winners • GlobeNewswire Inc. • 04/08/2026 01:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 08:39:11 PM
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections • GlobeNewswire Inc. • 04/02/2026 11:30:00 AM
- Annovis Publishes Historical Review of Buntanetap in The Scientist • GlobeNewswire Inc. • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:19:03 PM
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 09:06:04 PM
- Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results • GlobeNewswire Inc. • 03/16/2026 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 09:15:44 PM
- Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference • GlobeNewswire Inc. • 03/03/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 02:00:47 PM
- Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/28/2026 09:28:34 PM
- Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients • GlobeNewswire Inc. • 12/18/2025 09:35:00 PM
- Annovis to Host Corporate Update Webinar on January 28, 2026 • GlobeNewswire Inc. • 12/16/2025 01:00:00 PM
- Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group • GlobeNewswire Inc. • 12/03/2025 01:00:00 PM
- Annovis Announces Two Presentations at the CTAD 2025 Conference • GlobeNewswire Inc. • 11/24/2025 01:00:00 PM
